The pharmacological management of skeletal-related events from metastatic tumors

Orthopedics

Volumn 32, Issue 3, 2009, Pages 188-

  Hitron, Anna ^a,c   Adams, Val ^b  

^a UK HealthCare   (United States)

^b University of Kentucky   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; CAPSAICIN; CLODRONIC ACID; DENOSUMAB; DEXAMETHASONE; DULOXETINE; FENTANYL; IBANDRONIC ACID; IBUPROFEN; LIDOCAINE; METHADONE; MORPHINE; OSTEOCLAST DIFFERENTIATION FACTOR; OXYCODONE; PAMIDRONIC ACID; PARACETAMOL; PLACEBO; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; ZOLEDRONIC ACID; ANALGESIC AGENT; BONE DENSITY CONSERVATION AGENT; GLUCOCORTICOID;

ANEMIA; APPETITE; ARTICLE; BONE DISEASE; BONE MATRIX; BONE METASTASIS; BONE PAIN; BRADYCARDIA; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONSTIPATION; DRUG FEVER; DRUG MEGADOSE; DRUG PROTEIN BINDING; DYSPNEA; EDEMA; FLU LIKE SYNDROME; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; HYPOTENSION; INFECTION RISK; INJECTION SITE REACTION; INSOMNIA; JAW OSTEONECROSIS; KIDNEY DISEASE; LEUKOCYTOSIS; LIVER TOXICITY; LOADING DRUG DOSE; LUNG CANCER; MOOD DISORDER; MUSCULOSKELETAL PAIN; NAUSEA; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; OSTEOCLAST; OSTEOLYSIS; PLEURA EFFUSION; POSTMENOPAUSE OSTEOPOROSIS; PROGNOSIS; PROSTATE CANCER; RESPIRATORY DRIVE; SIDE EFFECT; SPINAL CORD COMPRESSION; SUPRAVENTRICULAR TACHYCARDIA; SYMPTOM; THROMBOSIS; UNSPECIFIED SIDE EFFECT; VOMITING; BONE TUMOR; FEMALE; MALE; METASTASIS; MULTIMODALITY CANCER THERAPY;

ANALGESICS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; COMBINED MODALITY THERAPY; DIPHOSPHONATES; FEMALE; GLUCOCORTICOIDS; HUMANS; HYPERCALCEMIA; MALE; NEOPLASM METASTASIS;

EID: 65649153708     PISSN: 01477447     EISSN: None     Source Type: Journal    
DOI: 10.3928/01477447-20090301-13     Document Type: Article

References (26)

1. Coleman RE, Guise TA, Lipton A, et al. Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference. Clin Cancer Res. 2008; 14(20):6387-6395.
2. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006; 12(20):6243s-6249s.
3. Mundy GR. Metastasis: metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002; 2(8):584.
4. Fred Saad RMCG. Targeting the receptor activator of nuclear factor-B (RANK) ligand in prostate cancer bone metastases. BJU International. 2008; 101(9):1071-1075.
5. Uehara H, Kim SJ, Karashima T, et al. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst. 2003; 95(6):458-470. (Pubitemid 36432420)
6. Yin JJ, Selander K, Chirgwin JM, et al. TGF-B signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest. 1999; 103(2):197-206. (Pubitemid 29053137)
7. Mantyh PW, Clohisy DR, Koltzenburg M, Hunt SP. Molecular mechanisms of cancer pain. Nat Rev Cancer. 2002; 2(3):201.
8. Wilkinson AN, Viola R, Brundage MD. Managing skeletal related events resulting from bone metastases. BMJ. 2008; (337):a2041.
9. Bartels RH, van der Linden YM, van der Graaf WT. Spinal extradural metastasis: review of current treatment options. CA Cancer J Clin. 2008; 58(4):245-259.
10. Delea T, McKiernan J, Brandman J, et al. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J Support Oncol. 2006; 4(7):341-347. (Pubitemid 44420137)
11. Stewart AF. Clinical practice: hypercalcemia associated with cancer. N Engl J Med. 2005; 352(4):373-379.
12. Klimo P, Kestle JRW, Schmidt MH. Clinical trials and evidence-based medicine for metastatic spine disease. Neurosurg Clin N Am. 2004; 15(4):549-564. (Pubitemid 39278449)
13. Klimo P, Schmidt MH. Sugical management of spinal metastases. Oncologist. 2004; 9(2):188-196.
14. Coleman RE. Bisphosphonates: clinical experience. Oncologist. 2004; 9(suppl 4):14-27.
15. Hortobagyi G, Theriault R, Lipton A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol. 1998; 16(6):2038-2044. (Pubitemid 28265038)
16. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002; 94(19):1458-1468.
17. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer. 2003; 98(8):1735-1744.
18. Zometa (zoledronic acid) injection for intravenous infusion. East Hanover, NJ: Novartis Pharmaceuticals; 2008.
19. Aredia (pamidronate disodium) for injection. East Hanover, NJ: Novartis Pharmaceuticals; 1998.
20. Ruggiero S, Drew S. Osteonecrosis of the jaw and bisphosphonate therapy. J Dent Res. 2007; 86(11):1013-1021.
21. Cole J, Patchell R. Metastatic epidural spinal cord compression. Lancet Neurology. 2008; 7(5):459-466.
22. Heimdal K, Hirschberg H, Slettebø H, Watne K, Nome O. High incidence of serious side effects of high-dose dexamethasone treatment in patients with epidural spinal cord compression. J Neurooncol. 1992; 12(2):141-144.
23. Loblaw D, Laperriere N. Emergency treatment of malignant extradural spinal cord compression: An evidence-based guideline. J Clin Oncol. 1998; 16(4):1613-1624. (Pubitemid 28175788)
24. Loblaw DA, Perry J, Chambers A, Laperriere NJ. Systematic review of the diagnosis and management of malignant extradural spinal cord compression: the Cancer Care Ontario Practice Guidelines Initiative's Neuro- Oncology Disease Site Group. J Clin Oncol. 2005; 23(9):2028-2037. (Pubitemid 46211383)
25. National Comprehensive Cancer Network (NCCN). Adult cancer pain. Practice guidelines in oncology. http://www.nccn.org/professionals/physician-gls/PDF/ pain.pdf. Updated May 6, 2008. Accessed January 3, 2009.
26. Body J-J, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res. 2006; 12(4):1221-1228. (Pubitemid 43342512)